Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Clinical trial NCT07184619 · RECRUITING
Trial details
- NCT number
- NCT07184619
- Sponsor
- Newron Pharmaceuticals SPA
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-23
- Primary completion
- 2026-12-31
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.